Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314569 | 0.89 | DRD2 (0.46) | DRD2 | |
| SCHEMBL11723708 | 0.81 | DRD2 (0.45) | DRD2SSTR1SSTR4DRD3HTR1A | |
| SCHEMBL5961771 | 0.79 | CA1 (0.47) | SSTR1SSTR4 | |
| SCHEMBL8320694 | 0.79 | CA1 (0.47) | SSTR1SSTR4 | |
| SCHEMBL1189936 | 0.79 | SSTR4 (0.44) | SSTR1SSTR4 | |
| SCHEMBL799005 | 0.79 | CA1 (0.47) | SSTR1SSTR4 | |
| SCHEMBL1749205 | 0.79 | SSTR4 (0.44) | SSTR1SSTR4 | |
| SCHEMBL4202085 | 0.79 | SSTR4 (0.44) | SSTR1SSTR4 | |
| SCHEMBL16072930 | 0.77 | DRD2 (0.39) | DRD2DRD3HTR1AHTR2AKCNH2 | |
| SCHEMBL19176840 | 0.77 | HRH3 (0.47) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-9624241-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2017-04-18 | — | — | US | disclosed |
| US-9227985-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | DRD2 200/4885SSTR1 4147/4885SSTR4 4512/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | DRD2 651/4885SSTR1 256/4885SSTR4 418/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | DRD2 651/4885SSTR1 256/4885SSTR4 418/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | DRD2 200/4885SSTR1 4147/4885SSTR4 4512/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | DRD2 651/4885SSTR1 256/4885SSTR4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.